BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...Entresto’s benchmark.The latest readout came on Oct. 8 when Cytokinetics Inc....
...Vericiguat has a Jan. 20, 2021 PDUFA date. Cytokinetics...
...are myosin activators that increase muscle contractility: Cytokinetics’ omecamtiv...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...By stephen hansen, associate editor Pivotal heart failure data 14 years in the making tripped up Cytokinetics...
...expected in 1H21.On Monday, Cytokinetics rose 19% to $28.61 on MyoKardia’s M&A news. In July, Cytokinetics...
...partnership. Cytokinetics licensed the compound’s China rights to Ji Xing Pharmaceuticals in July.Outside of CV, Cytokinetics...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

...could be in heart failure patients with preserved ejection fraction (HFpEF).In July, fellow CV company Cytokinetics Inc....
...rights to mavacamten for $85 million. It had gained them under a 2012 collaboration with MyoKardia.Cytokinetics...
...of CK-274 in obstructive HCM are expected by year end. CK-274 is also a cardiac myosin inhibitor.Cytokinetics...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...not be first-in-class, noting that sometimes those compounds represent unproven risk. According to BioCentury’s BCIQ database, Cytokinetics Inc....
...in development for hypertrophic cardiomyopathy. The company’s CK-274 is in Phase II testing for hypertrophic cardiomyopathy. Cytokinetics...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...Cytokinetics in deals with Chinese biotech, investor Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in...
...will receive an undisclosed upfront payment and up to $200 million in milestones plus royalties. Cytokinetics...
...$85 million and made a $50 million equity investment in Cytokinetics at $25 per share. Cytokinetics...
BioCentury | Jul 14, 2020
Deals

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

...million from Chiron Corp. co-founder and Kainomyx Chairman William Rutter, Open Philanthropy and the Spudiches. Cytokinetics Inc....
...and receive an undisclosed equity stake and single-digit royalties. James Spudich is a co-founder of Cytokinetics...
...licensed exclusive rights for the use of Kiadis’ platform for two other preclinical programs. BioCentury Staff gaboxadol (OV101) Cytokinetics Inc. Merck...
BioCentury | May 11, 2020
Product Development

Data validate MyoKardia’s mavacamten in subset of cardiomyopathy, suggest broader applications

...to $96.90. After market close, the company proposed to raise $450 million in a follow-on. Cytokinetics Inc....
...NASDAQ:CYTK) was also up $5.23 (33.23%) to $20.99 on Monday. According to BioCentury’s BCIQ database, Cytokinetics...
...for hypertrophic cardiomyopathy. The company’s Phase II hypertrophic cardiomyopathy candidate CK-274 is in Phase II. Cytokinetics...
BioCentury | May 5, 2020
Deals

BioMarin builds on gene therapy momentum with DiNAQOR deal in cardiomyopathy

...underlying biology. Mavacamten from MyoKardia Inc. (NASDAQ:MYOK) is in Phase III testing; while CK-247 from Cytokinetics Inc....
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...been on both sides of the table -- he was founder, president and CEO of Cytokinetics Inc....
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...The companies he’s watching include Cytokinetics Inc. (NASDAQ:CYTK), MyoKardia Inc. (NASDAQ:MYOK) and Esperion Therapeutics Inc. (NASDAQ:ESPR). Cytokinetics...
...with data from the Phase III EXPLORER-HCM trial in obstructive HCM expected in 2H20, but Cytokinetics...
Items per page:
1 - 10 of 415
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...Entresto’s benchmark.The latest readout came on Oct. 8 when Cytokinetics Inc....
...Vericiguat has a Jan. 20, 2021 PDUFA date. Cytokinetics...
...are myosin activators that increase muscle contractility: Cytokinetics’ omecamtiv...
BioCentury | Oct 8, 2020
Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

...By stephen hansen, associate editor Pivotal heart failure data 14 years in the making tripped up Cytokinetics...
...expected in 1H21.On Monday, Cytokinetics rose 19% to $28.61 on MyoKardia’s M&A news. In July, Cytokinetics...
...partnership. Cytokinetics licensed the compound’s China rights to Ji Xing Pharmaceuticals in July.Outside of CV, Cytokinetics...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

...could be in heart failure patients with preserved ejection fraction (HFpEF).In July, fellow CV company Cytokinetics Inc....
...rights to mavacamten for $85 million. It had gained them under a 2012 collaboration with MyoKardia.Cytokinetics...
...of CK-274 in obstructive HCM are expected by year end. CK-274 is also a cardiac myosin inhibitor.Cytokinetics...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...not be first-in-class, noting that sometimes those compounds represent unproven risk. According to BioCentury’s BCIQ database, Cytokinetics Inc....
...in development for hypertrophic cardiomyopathy. The company’s CK-274 is in Phase II testing for hypertrophic cardiomyopathy. Cytokinetics...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...Cytokinetics in deals with Chinese biotech, investor Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in...
...will receive an undisclosed upfront payment and up to $200 million in milestones plus royalties. Cytokinetics...
...$85 million and made a $50 million equity investment in Cytokinetics at $25 per share. Cytokinetics...
BioCentury | Jul 14, 2020
Deals

July 13 Quick Takes: Spudich, Rutter to lead start-up Kainomyx; plus deals for Ovid-Angelini, Dewpoint-Merck and Kiadis-Sanofi

...million from Chiron Corp. co-founder and Kainomyx Chairman William Rutter, Open Philanthropy and the Spudiches. Cytokinetics Inc....
...and receive an undisclosed equity stake and single-digit royalties. James Spudich is a co-founder of Cytokinetics...
...licensed exclusive rights for the use of Kiadis’ platform for two other preclinical programs. BioCentury Staff gaboxadol (OV101) Cytokinetics Inc. Merck...
BioCentury | May 11, 2020
Product Development

Data validate MyoKardia’s mavacamten in subset of cardiomyopathy, suggest broader applications

...to $96.90. After market close, the company proposed to raise $450 million in a follow-on. Cytokinetics Inc....
...NASDAQ:CYTK) was also up $5.23 (33.23%) to $20.99 on Monday. According to BioCentury’s BCIQ database, Cytokinetics...
...for hypertrophic cardiomyopathy. The company’s Phase II hypertrophic cardiomyopathy candidate CK-274 is in Phase II. Cytokinetics...
BioCentury | May 5, 2020
Deals

BioMarin builds on gene therapy momentum with DiNAQOR deal in cardiomyopathy

...underlying biology. Mavacamten from MyoKardia Inc. (NASDAQ:MYOK) is in Phase III testing; while CK-247 from Cytokinetics Inc....
BioCentury | May 2, 2020
Deals

At the end of this crisis, the biopharma ecosystem might emerge with a better landscape

...been on both sides of the table -- he was founder, president and CEO of Cytokinetics Inc....
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...The companies he’s watching include Cytokinetics Inc. (NASDAQ:CYTK), MyoKardia Inc. (NASDAQ:MYOK) and Esperion Therapeutics Inc. (NASDAQ:ESPR). Cytokinetics...
...with data from the Phase III EXPLORER-HCM trial in obstructive HCM expected in 2H20, but Cytokinetics...
Items per page:
1 - 10 of 415